Condition
Advanced or Recurrent Solid Tumors
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
P 1 (4)
P 2 (1)
Trial Status
Completed2
Recruiting2
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04962867Phase 2RecruitingPrimary
NCCH2006/MK010 Trial (FORTUNE Trial)
NCT06541639Phase 1RecruitingPrimary
EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors
NCT03426254Phase 1WithdrawnPrimary
Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors
NCT01285453Phase 1CompletedPrimary
Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors
NCT01286987Phase 1CompletedPrimary
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Showing all 5 trials